Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (1) Comply with the diagnostic criteria for chronic non-atrophic gastritis.~* (2) Age between 18 to 65 years.~* (3) Voluntarily participate the clinical trials and sign informed consent.~Exclusion Criteria:~* (1) Subjects with history of gastric surgery.~* (2) Patients with complicated and special types of gastritis, peptic ulcer, hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological diagnosis of suspected malignant change.~* (3) Patients with atrophy and/or intestinal metaplasia through pathological examination showed;.~* (4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system (above grade II of cardiac function; Cr value above the upper limit of normal value), or serious diseases affecting their survival, such as cancer or AIDS;~* (5) Patients who have used Chinese and Western medicine to treat chronic non-atrophic gastritis in the last two weeks;~* (6) Subjects with psychiatric disorders or a history of alcohol/drug abuse;~* (7) Pregnant women, woman who are preparing for pregnancy, lactating women;~* (8) Patients who are allergic constitution or allergic to known ingredients of test drugs;~* (9) Those who have participated in or are participating in other drug clinical trials in the past 3 months;~* (10) The syndrome differentiation is not clear or there are too many and complicated syndromes for the subjects;~* (11) Subjects that researchers do not consider appropriate to participate in clinical trials.~* (12) Patients with poor compliance are not allowed to participate in this trial.~  * Those who meet one or more of the above exclusion criteria cannot be included in the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Houtou Jianeweiling tablet ) (Type: EXPERIMENTAL): Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
- Control group (Omeprazole enteric-coated tablet) (Type: ACTIVE_COMPARATOR): Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).